Pfizer to acquire minority stake in CStone Pharmaceuticals for $200m
This article was originally published here
Under the deal, CStone and Pfizer will involve in the development and commercialisation of CStone’s sugemalimab, an investigational anti-PD-L1 monoclonal antibody, in mainland China. They will also co-develop
The post Pfizer to acquire minority stake in CStone Pharmaceuticals for $200m appeared first on Pharmaceutical Business review.
Leave a Reply
Want to join the discussion?Feel free to contribute!